7 recruiting, 4 completed, 4 terminated, 3 unknown. 10 Phase 2, 5 Not applicable, 5 Phase 1, 3 Phase 4, 1 Phase 3.
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Advanced NSCLC | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 24 | 2026-09-21 | 2026-10-14 |
| Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy JS207 injection +docetaxel, JS207 injection +JS004 injection, JS207 injection - Advanced NSCLC | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 18 | 2025-07-15 | 2026-09-25 |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Cabozantinib, Atezolizumab - Lung Cancer, NSCLC Stage IV | Phase 2 | Not yet recruiting | Jun Zhang, MD, PhD | 40 | 2024-12-01 | 2024-05-08 |
| Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine - Advanced NSCLC | Not applicable | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-09-01 | 2024-12-30 |
| Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine - Advanced NSCLC | Not applicable | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-09-01 | 2024-12-30 |
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Tislelizumab, Anlotinib - Advanced NSCLC | Phase 4 | Not yet recruiting | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | 33 | 2024-07-01 | 2024-04-10 |
| Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine - Advanced NSCLC | Phase 2 | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-03-11 | 2024-12-30 |
| Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine - Advanced NSCLC | Phase 2 | Recruiting | The First Affiliated Hospital of Nanchang University | 10 | 2024-03-11 | 2024-12-30 |
| A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor HB0025, Pemetrexed, Paclitaxel - Advanced NSCLC, Advanced Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 282 | 2024-01-31 | 2025-01-23 |
| Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations CT053PTSA - Advanced NSCLC | Phase 2 | Withdrawn | Sunshine Lake Pharma Co., Ltd. | 2022-11-27 | 2026-05-14 | |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed - Advanced NSCLC, Metastatic Lung Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 90 | 2022-11-22 | 2026-06-23 |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Gene Profile explore - Advanced NSCLC | Phase 4 | Completed | AstraZeneca | 182 | 2022-02-25 | 2025-09-11 |
| A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC camrelizumab + famitinib, famitinib, docetaxel - Advanced NSCLC | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 1 | 2022-01-06 | 2023-08-16 |
| Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer REGN5093-M114, Cemiplimab - Advanced NSCLC | Phase 1 | Terminated | Regeneron Pharmaceuticals | 30 | 2021-11-09 | 2025-11-03 |
| Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients nonintervention - Advanced NSCLC, Circulating Tumor Cells | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2020-01-15 | 2020-01-18 | |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Nivolumab, Oxaliplatin, Ipilimumab - Advanced NSCLC | Phase 1 / Phase 2 | Active not recruiting | Hatim Husain | 30 | 2019-08-14 | 2025-05-28 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
| Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01) radiotherapy - Advanced Nsclc | Not applicable | Completed | Xinqiao Hospital of Chongqing | 240 | 2017-07-01 | 2024-03-05 |
| AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Alflutinib - Advanced NSCLC | Not applicable | Terminated | Allist Pharmaceuticals, Inc. | 116 | 2017-06-01 | 2025-04-03 |
| Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Thalidomide, pemetrexed, cisplatin - Advanced Nsclc | Phase 2 | Unknown | Qilu Hospital of Shandong University | 232 | 2016-12-01 | 2019-06-05 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Lung Neoplasms (4) · Adenocarcinoma (2) · Carcinoma, Adenosquamous (2) · Carcinoma, Squamous Cell (2) · Endometrial Neoplasms (1) · Motor Activity (1) · Neoplasm Metastasis (1) · Neoplastic Cells, Circulating (1) · Recurrence (1)
Neoplasms (11) · Neoplasms by Site (10) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Lung Neoplasms (5) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Complex and Mixed (2) · Neoplasms, Glandular and Epithelial (2)
Radiotherapy (5) · Immune Checkpoint Inhibitors (4) · Carboplatin (3) · Cyclophosphamide (3) · fludarabine (3) · Cisplatin (2) · Docetaxel (2) · Nivolumab (2) · Pemetrexed (2) · aldesleukin (2) · Control Groups (1) · Interleukin-2 (1) · Ipilimumab (1) · Oxaliplatin (1) · Paclitaxel (1)
The First Affiliated Hospital of Nanchang University (4) · Allist Pharmaceuticals, Inc. (1) · AstraZeneca (1) · German Cancer Research Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hangzhou Huasai Biomedicine Co., Ltd. (1) · Hatim Husain (1) · Huabo Biopharm Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jun Zhang, MD, PhD (1) · Mirati Therapeutics Inc. (1) · National Cancer Institute (NCI) (1) · Qilu Hospital of Shandong University (1) · Regeneron Pharmaceuticals (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
China (13) · United States (6) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1)
Ben Creelan, M.D. (1) · Caicun Zhou, PhD. (1) · Hatim Husain (1) · James C Yang, M.D. (1) · Joachim Wiskemann, Dr. (1) · Jun Zhang, MD, PhD (1) · Jundong Li, PhD. (1) · Kai LI, professor (1) · Li Zhang, MD (1) · Michael Thomas, Prof. Dr. (1) · Simone Hummler, Dr. (1) · Xiuwen Wang, MD.PhD (1) · Yayi He, MD,PHD (1)
PMID 27430336, PMID 29480444, PMID 30714987, PMID 32007598, PMID 34385708, PMID 41326340